Coffee consumption and hepatocellular carcinoma in patients with HBeAg negative chronic hepatitis B

Publication date: Available online 12 December 2019Source: Journal of the Formosan Medical AssociationAuthor(s): Chien-Lin Chen, Wei-Chuan Chang, Ching-Sheng Hsu
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research

Related Links:

In conclusion, the molecular mechanism of anti-HCC of B. batryticatus can be related to the tumor microenvironment to some extent. B. batryticatus may exert its anti-cancer effects and improve prognosis of patients by regulating macrophages M1 in VIR and NVIR through acting on different targets.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Earlier normalization of alanine aminotransferase (ALT) levels during treatment of chronic hepatitis B is independently associated with a reduced risk of hepatocellular carcinoma (HCC), researchers from South Korea report.Reuters Health Information
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news
Condition:   Hepatocellular Carcinoma Interventions:   Drug: P1101 (Ropeginterferon alfa-2b);   Drug: Nivolumab Sponsors:   National Taiwan University Hospital;   PharmaEssentia Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 17 January 2020Source: Clinics and Research in Hepatology and GastroenterologyAuthor(s): Seung In Seo, Hyoung Su Kim, Bo Kyung Yang, Jin Gu Kang, Woon Geon Shin, Jin Heon Lee, Hak Yang Kim, Myoung Kuk JangSummaryBackground and aimsThe risk factors for hepatocellular carcinoma (HCC) in immune inactive chronic hepatitis B (CHB) have not been clarified. The aim of this study was to investigate the predictive factors for HCC inimmune inactive CHB.MethodsA total of 337 patients in immune inactive CHB were consecutively enrolled in Kangdong Sacred Heart Hospital from 1995 to 2017. Univariate an...
Source: Clinics and Research in Hepatology and Gastroenterology - Category: Gastroenterology Source Type: research
Condition:   Hepatocellular Carcinoma Interventions:   Drug: P1101 (Ropeginterferon alfa-2b);   Drug: Nivolumab Sponsors:   National Taiwan University Hospital;   PharmaEssentia Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The burden of hepatocellular carcinoma (HCC) is highest in East Asia and Africa, although its incidence and mortality are rapidly rising in the United States and Europe. With the implementation of hepatitis B vaccination and hepatitis C treatment programmes worldwide, the epidemiology of HCC is shifting away from a disease predominated by viral hepatitis – an increasing proportion of cases are now attributable to non-alcoholic steatohepatitis. Surveillance using ultrasound, with or without alpha-fetoprotein, every 6 months has been associated with improved early detection and improved overall survival; however, lim...
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Review Source Type: research
This study may shed light on the development of a novel class of anti-HBV agents. PMID: 31954513 [PubMed - as supplied by publisher]
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
Abstract Hepatocellular carcinoma (HCC) accounts for about 80-90% of all liver cancers and is found to be the third most common cause of cancer mortality in the Asia-Pacific region. Risk factors include hepatitis B and C virus, cirrhosis, aflatoxin-contaminated food, alcohol, and diabetes. Surgically removing the tumor tissue seems effective but a high chance of recurrence has led to an urgent need to develop novel molecules for the treatment of HCC. Clinical management with sorafenib is found to be effective but it is only able to prolong survival for a few months. Various side effects like gastrointestinal and a...
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
lncRNA HAND2‑AS1 mediates the downregulation of ROCK2 in hepatocellular carcinoma and inhibits cancer cell proliferation, migration and invasion. Mol Med Rep. 2020 Jan 10;: Authors: Jiang L, He Y, Shen G, Ni J, Xia Z, Liu H, Cao Y, Li X Abstract Long noncoding (lnc)RNA HAND2‑AS1 inhibits the development of several human malignancies. The role of HAND2‑AS1 was investigated in hepatocellular carcinoma (HCC). It was found that levels of HAND2‑AS1 in serum were significantly lower, while serum levels of Rho‑associated protein kinase 2 (ROCK2) in HCC patients were significantly increased compared ...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Publication date: Available online 10 January 2020Source: Genes &DiseasesAuthor(s): Yong LiaoAbstractDespite the tremendous progresses toward our understanding of the mechanisms of how liver cancer was developed, the therapeutic outcomes of liver cancer in the clinic have very limited improvement within the past three decades or so. In addition, both the incidence and mortality of liver cancer worldwide are not dropping, but increasing steadily, in the last decade. Thus, it is time for us to rethink what has been wrong and how could we do better in the upcoming years, in order to achieve our goal of improving the thera...
Source: Genes and Diseases - Category: Genetics & Stem Cells Source Type: research
More News: Cancer & Oncology | Carcinoma | Coffee | General Medicine | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Liver Cancer